Text/Yangcheng Evening News All Media Reporter Chen Hui
Picture/Provided by respondents
The incidence of malignant B-cell lymphoma in my country is increasing at a rate of 3% every year. Among more than 100 types, extranodal NK/T-cell lymphoma is easy to relapse, difficult to Once the patient is diagnosed with poor prognosis, it has become an urgent bottleneck in the field of malignant lymphoma treatment. The reporter learned on September 28 that a multi-center study led by the Lymphoma Center of Sun Yat-sen University Cancer Hospital showed that the use of the new domestically produced PDL-1 monoclonal antibody approved in my country last year was used to treat relapsed and refractory extranodal NKT cell lymphoma. Afterwards, the patient’s tumor complete response rate (CR) was as high as 37.2%. This study will provide a new option with more precise curative effect and fewer side effects for the treatment of NKT lymphoma worldwide.
Patients with limited benefit from conventional regimens
Professor Huang Huiqiang from the Lymphoma Center of Sun Yat-sen University Cancer Hospital, who is in charge of the study, introduced that extranodal NK/T cell lymphoma is a subtype of mature T cell and NK cell lymphoma. A multi-center pathological analysis of 10,002 patients in my country in 2012, the disease accounts for about 6% of all lymphoma subtypes, and patients with disease progression after receiving standard asparaginase-based regimens lack effective treatment. Salvage therapy has poor prognosis, and clinicians are often helpless for such patients. Due to the high degree of malignancy and strong invasiveness, the disease is dangerous, the progression is rapid, and the survival period is extremely short. The 1-year survival rate of patients is usually less than 20%.
Among the currently approved targeted drugs in China, the complete remission rate of monotherapy is very low, about 6%. There is a significant unmet need for treatment in patients after failure of first-line treatment regimens.
The complete response rate of the new treatment regimen is as high as 37.2%
More than two years ago, a national multi-center study led by Prof. Huiqiang Huang aimed to evaluate a new domestically produced PDL-1 suglimumab in the treatment of relapsed and refractory NK/T-cell lymphoma efficacy and safety. So far, this study is the first registered clinical study at home and abroad to evaluate PD-L1 monoclonal antibody in the treatment of R/R ENKTL.
The results of this study show that PDL-1 suglimumab significantly improved objective response rates compared to previous drugs; in 78 evaluable patients, an independent imaging review committee assessed The objective remission rate was 46.2%, of which the complete remission rate reached 37.2%. Compared with the previously reported treatment results, the complete remission rate increased by as much as 6 times.
“Our study also found that the duration of the drug’s effectiveness was also quite long. The 6-month and 12-month response rates were 90.8% and 86.0%, respectively, the longest in one case. The patient has been in complete remission for more than 3 years.” Huang Huiqiang said that the safety of the drug is also quite high, its adverse reactions are few, and it can be controlled and recovered. And the incidence of clinical immune-related toxicity is low. Some patients have used 65 courses of treatment for 3 and a half years, and no common immune toxicity of immune monoclonal antibody has been observed.
Professor Huang Huiqiang’s team
Immune targeted therapy to improve efficacy is the future direction
Professor Huang Huiqiang said that NK/T cell lymphoma is uncommon in terms of overall incidence, but it is more common in Southeast Asia (including China) and less common in Western countries. , is relatively rare in northern China compared to southern China.
NK/T-cell lymphoma is a highly heterogeneous disease. In most patients, the disease originated in the nasal cavity in the early stage, and in some patients, the disease originated in the intestine, testis or skin in the early stage. The treatment of early stage patients is mainly radiotherapy, and the treatment of advanced stage patients is mainly systemic chemotherapy.
In addition, the recurrence rate of NK/T cell lymphoma is still relatively high. After radiotherapy and chemotherapy in early stage patients, 10%-20% of patients eventually relapse; At least half will relapse; even with other new chemotherapy drugs or combined with autologous hematopoietic stem cell transplantation, a considerable number of patients will relapse, so this is the biggest challenge in NK/T cell lymphoma treatment.
Source | Yangcheng Evening News·Yangcheng Pie
Editor | Xue Renzheng
Proofreading | Zhao Dandan